Compare Niramas Utama Tbk. (JELI) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Niramas Utama Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Niramas Utama Tbk. trades at Rp515 (market cap 670.98B, 3.31M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Niramas Utama Tbk. is far larger — about 6.4× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| JELI | SCPI | |
|---|---|---|
Market Cap | 670.98B | 104.4B |
Volume | 3.31M | — |
Lot | 33.07K | — |
Turnover | 1.71B | — |
Average Price | 516.6 | — |
Value | 1.71B | — |
Indicative Equilibrium Price | 515 | — |
Indicative Equilibrium Volume | 680 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Niramas Utama Tbk.
PT. Niramas Utama Tbk. (the Company) formerly PT Nata Sari Raya was established based on Notarial Deed No. 86 dated 22 November 1990, by Notary Samsul Hadi, S.H. The Company started its commercial operations in 1994. The parent entity and the ultimate parent entity of the Company are PT Niramas Utama International and PT Supra Sentral Investama
Read more on JELI →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
